{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-009279","form_type":"8-K","ticker":"ANVS","cik":"0001477845","company_name":"Annovis Bio, Inc.","filed_at":"2025-02-05T23:59:59+00:00","discovered_at":"2026-05-14T18:03:03.738836+00:00","generated_at":"2026-05-27T02:33:30.954856+00:00","sec_items":["1.01","8.01","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Annovis Bio closes $21M public offering of 5.25M units with warrants at $4.00/unit","bullets":["Offering of 5,250,000 units (1 share + 1 warrant) at $4.00 per unit; gross proceeds $21M.","Warrants exercisable at $5.00 per share, immediately exercisable, 5-year term.","Net proceeds to fund Phase 3 study of Buntanetap for Alzheimer's disease and working capital.","Offering closed on February 4, 2025; underwritten by ThinkEquity LLC."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-009279","json":"https://secwatch.observer/filing/0001104659-25-009279.json","markdown":"https://secwatch.observer/filing/0001104659-25-009279.md","text":"https://secwatch.observer/filing/0001104659-25-009279.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1477845/000110465925009279/0001104659-25-009279-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1477845/000110465925009279/tm255497d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-27T02:33:30.954856+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}